Research
Hormonal
Adverse events (AEs) were more common in the T2D group (78.3% vs. 50.0%).
Healthcare providers should monitor for gastrointestinal symptoms in T2D patients using tirzepatide.
GoodSupportsmedium confidence
AEs were more common in the T2D group (78.3% vs. 50.0%, P = 0.033).
Why this rating
The study is a prospective observational cohort study.
Source
Tirzepatide-induced Weight Loss in Overweight or Obese Midlife Adults with and without Type 2 Diabetes: A Real-world Comparative Cohort Study
Prabhat Kumar Agrawal et al. · Journal of Mid-life Health · 2026
DOI 10.4103/jmh.jmh_373_25
cohort · n=93
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →